NCT04658927View on ClinicalTrials.gov

Dextenza With ILUX for Treatment of MGD

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

January 11, 2021

Study Completion Date

May 30, 2021

Conditions
Meibomian Gland DysfunctionEvaporative Dry Eye
Interventions
DRUG

Dexamethasone, 0.4mg

iLUX + dextenza

DRUG

Prednisone acetate

Prednisolone acetate 1% and iLux

OTHER

Control

iLUX alone.

Trial Locations (1)

60555

Warrenville EyeCare & LASIK, Warrenville

All Listed Sponsors
lead

Warrenville Eyecare

OTHER

NCT04658927 - Dextenza With ILUX for Treatment of MGD | Biotech Hunter | Biotech Hunter